Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban

<b>Background/Objectives</b>: The aim of the present study was to develop lactose-free formulations of rivaroxaban, a novel oral anticoagulant used for the treatment and prevention of blood clotting. As a BCS Class II drug, rivaroxaban is characterized by poor solubility in aqueous media, posing a s...

Descrición completa

Detalles Bibliográficos

Principais autores:	Daniel Zakowiecki, Peter Edinger, Markos Papaioannou, Michael Wagner, Tobias Hess, Jadwiga Paszkowska, Marcela Staniszewska, Daria Myslitska, Michal Smolenski, Justyna Dobosz, Grzegorz Garbacz, Dorota Haznar Garbacz
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2024-11-01
Series:	Pharmaceutics
Assuntos:	rivaroxaban lactose-free formulation excipient calcium phosphates pellets MUPS
Acceso en liña:	https://www.mdpi.com/1999-4923/16/11/1485
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!